IO Biotech (IOBT) TD Cowen 45th Annual Healthcare Conference summary

Strategic vision and platform overview

• Focus on innovative, off-the-shelf cancer vaccines leveraging the T-win platform for broad applicability across tumor types and patient populations.

• Lead asset, Cylembio (IO102-IO103), targets first-line unresectable metastatic melanoma, with expansion into head and neck and lung cancers.

• Preclinical pipeline includes IO112 (targeting Arginase 1) and IO170 (targeting TGF-beta), aiming to address additional solid tumors.

• T-win technology may extend beyond oncology, with future potential in infectious diseases.

Clinical development and data highlights

• Phase I/II melanoma trial showed 80% overall response rate, 50% complete response, and 25.5 months median PFS, with no systemic toxicity, leading to FDA breakthrough therapy designation.

• Pivotal phase III trial in melanoma fully recruited 407 patients, comparing Cylembio plus pembrolizumab to pembrolizumab alone; primary endpoint is PFS.

• Phase II basket trials in lung and head and neck cancers met primary endpoints, with confirmed ORR of 48% in lung and 44.4% in head and neck; median PFS of 8.1 and 6.6 months, respectively.

• Perioperative trials in melanoma and head and neck are ongoing, with first data expected later this year.

Market opportunity and unmet need

• Melanoma is the fifth most common cancer in the U.S., with a 23% five-year survival rate and a projected metastatic market of $13B by 2030, growing at 10% annually.

• Lung cancer is the second largest indication globally, with a $60B market by 2030 and only 28% five-year survival for stage IV.

• Head and neck cancer market expected to reach $5B by 2030, with a 6% annual growth rate and 60% of patients failing current treatments.

• Cylembio aims to address high unmet needs by offering rapid, accessible, and scalable treatment with a favorable safety profile.